These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20031786)

  • 1. One-year costs in patients with a history of or at risk for atherothrombosis in the United States.
    Mahoney EM; Wang K; Cohen DJ; Hirsch AT; Alberts MJ; Eagle K; Mosse F; Jackson JD; Steg PG; Bhatt DL;
    Circ Cardiovasc Qual Outcomes; 2008 Sep; 1(1):38-45. PubMed ID: 20031786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economic implications of treating atherothrombotic disease in Australia, from the government perspective.
    Ademi Z; Liew D; Hollingsworth B; Wolfe R; Steg GP; Bhatt DL; Reid CM;
    Clin Ther; 2010 Jan; 32(1):119-32; discussion 106-7. PubMed ID: 20171418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH Registry.
    Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Steg PG; Cannon CP; Brennan DM; Bhatt DL;
    Crit Pathw Cardiol; 2009 Jun; 8(2):91-7. PubMed ID: 19417637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry.
    Smolderen KG; Bell A; Lei Y; Cohen EA; Steg PG; Bhatt DL; Mahoney EM;
    Can J Cardiol; 2010 Oct; 26(8):297-305. PubMed ID: 20931098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year vascular hospitalisation rates and associated costs in patients at risk of atherothrombosis in France and Germany: highest burden for peripheral arterial disease.
    Smolderen KG; Wang K; de Pouvourville G; Brüggenjürgen B; Röther J; Zeymer U; Parhofer KG; Steg PG; Bhatt DL; Magnuson EA;
    Eur J Vasc Endovasc Surg; 2012 Feb; 43(2):198-207. PubMed ID: 22001145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry).
    Krempf M; Parhofer KG; Steg PG; Bhatt DL; Ohman EM; Röther J; Goto S; Pasquet B; Wilson PW;
    Am J Cardiol; 2010 Mar; 105(5):667-71. PubMed ID: 20185014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular event rates in patients with cerebrovascular disease and atherothrombosis at other vascular locations: results from 1-year outcomes in the Japanese REACH Registry.
    Uchiyama S; Goto S; Matsumoto M; Nagai R; Origasa H; Yamazaki T; Shigematsu H; Shimada K; Yamada N; Bhatt DL; Steg PG; Ikeda Y;
    J Neurol Sci; 2009 Dec; 287(1-2):45-51. PubMed ID: 19815240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design.
    Ohman EM; Bhatt DL; Steg PG; Goto S; Hirsch AT; Liau CS; Mas JL; Richard AJ; Röther J; Wilson PW;
    Am Heart J; 2006 Apr; 151(4):786.e1-10. PubMed ID: 16569533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacoeconomic analysis: results of the REACH registry].
    Suárez C; Abadía C; Echevarria A
    Med Clin (Barc); 2009 Sep; 132 Suppl 2():41-3. PubMed ID: 19631839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry.
    Ademi Z; Liew D; Hollingsworth B; Steg PG; Bhatt DL; Reid CM;
    Am J Cardiovasc Drugs; 2010; 10(2):85-94. PubMed ID: 20334445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis.
    Boden WE; Cherr GS; Eagle KA; Cannon CP; Califf RM; Hirsch AT; Alberts MJ; Criqui M; Creager MA; Massaro JM; D'Agostino RB; Steg PG; Bhatt DL;
    Crit Pathw Cardiol; 2010 Sep; 9(3):116-25. PubMed ID: 20802264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug treatment and cost of cardiovascular disease in Australia.
    Ademi Z; Liew D; Chew D; Conner G; Shiel L; Nelson M; Soman A; Steg G; Bhatt DL; Reid C;
    Cardiovasc Ther; 2009; 27(3):164-72. PubMed ID: 19689615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risk profile and outcome of patients with abdominal aortic aneurysm in out-patients with atherothrombosis: data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry.
    Baumgartner I; Hirsch AT; Abola MT; Cacoub PP; Poldermans D; Steg PG; Creager MA; Bhatt DL;
    J Vasc Surg; 2008 Oct; 48(4):808-14. PubMed ID: 18639426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence, recognition and treatment of cardiovascular risk factors in outpatients with atherothrombosis in Israel.
    Barski L; Porath A; Novack V; Jotkowitz A
    Isr Med Assoc J; 2007 May; 9(5):376-9. PubMed ID: 17591377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
    Kumar A; Fonarow GC; Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Boden WE; Steg PG; Shao M; Bhatt DL; Cannon CP;
    Crit Pathw Cardiol; 2009 Sep; 8(3):104-11. PubMed ID: 19726929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes.
    Bhatt DL; Peterson ED; Harrington RA; Ou FS; Cannon CP; Gibson CM; Kleiman NS; Brindis RG; Peacock WF; Brener SJ; Menon V; Smith SC; Pollack CV; Gibler WB; Ohman EM; Roe MT;
    Eur Heart J; 2009 May; 30(10):1195-202. PubMed ID: 19339264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry.
    Suárez C; Zeymer U; Limbourg T; Baumgartner I; Cacoub P; Poldermans D; Röther J; Bhatt DL; Steg PG;
    Vasc Med; 2010 Aug; 15(4):259-65. PubMed ID: 20724374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis.
    Goto S; Bhatt DL; Röther J; Alberts M; Hill MD; Ikeda Y; Uchiyama S; D'Agostino R; Ohman EM; Liau CS; Hirsch AT; Mas JL; Wilson PW; Corbalán R; Aichner F; Steg PG;
    Am Heart J; 2008 Nov; 156(5):855-63, 863.e2. PubMed ID: 19061698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry).
    Cannon CP; Rhee KE; Califf RM; Boden WE; Hirsch AT; Alberts MJ; Cable G; Shao M; Ohman EM; Steg PG; Eagle KA; Bhatt DL;
    Am J Cardiol; 2010 Feb; 105(4):445-52. PubMed ID: 20152237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.